Clinical trialNCT00154180UnknownPhase 4Interventional

Kronos Early Estrogen Prevention Study (KEEPS)

SponsorKronos Longevity Research InstituteEnrollment728ArteriosclerosisMenopause

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Dennis M Black, PhD
University of California, San Francisco
Principal Investigator
clinicaltrials.gov ↗
Frederick Naftolin, MD, PhD
Kronos Longevity Research Institute
Study Director
clinicaltrials.gov ↗
Howard Hodis, MD
University of Southern California
Principal Investigator
clinicaltrials.gov ↗
Matthew Budoff, MD
University of California, Los Angeles
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Michael Mendelsohn, MD
Tufts Medical Center
Principal Investigator
clinicaltrials.gov ↗
S Mitchell Harman, MD, PhD
Kronos Longevity Research Institute
Study Director
clinicaltrials.gov ↗
Sanjay Asthana, MD
University of Wisconsin, Madison
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Kronos Longevity Research Institute
Phoenix, Arizona, United States
University of California, San Francisco
San Francisco, California, United States
Yale University Medical Center
New Haven, Connecticut, United States
Brigham and Women'S Hospital
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Columbia Presbyterian Hospital
New York, New York, United States
Albert Einstein College of Medicine
The Bronx, New York, United States
University of Utah
Salt Lake City, Utah, United States
University of Washington/va Puget Sound, Hcs
Seattle/Tacoma, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CEE , progesterone, estradiol patch or placebo for eachCEE, progesterone, transdermal patch or the placeboConjugated equine estrogens 0.45 mg/dayProgesterone →Transdermal estradiol, 50 mcg/day

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2005
Primary completion: 31 May 2012
Completion: 31 Jul 2012
Last update posted: 14 Sept 2009
Registered enrollment: 728
Registry id: NCT00154180

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.